Organicell Begins Up-Listing Process On NASDAQ Exchange

Rhea-AI Summary

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is pursuing an up-listing to NASDAQ Capital Market, aiming to enhance liquidity and visibility for shareholders. To qualify, the company must meet specific criteria, including $5 million in shareholder equity and a minimum share price of $4.00. This may necessitate raising more capital through offerings or conducting a reverse stock split. CEO Albert Mitrani emphasizes the strategic importance of this move for funding clinical trials. However, there are no guarantees that the company will meet the NASDAQ requirements or secure listing.

Positive

• None.

Negative

• Potential need for additional capital raising to meet NASDAQ requirements.
• Possible implementation of a reverse stock split to achieve minimum trading price.
• Uncertainty regarding meeting NASDAQ's listing criteria.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC.

To qualify and be approved for such up-listing, the Company would be required to meet all financial, share price and corporate governance listing requirements of NASDAQ, which for the NASDAQ Capital Market includes a minimum of $5 million in shareholder equity and a minimum trading price of $4.00 per share. In order to meet these criteria, the Company would likely need to raise additional capital in one or more private or public offerings, as well as implement a reverse stock split or other recapitalization to meet the minimum trading price requirement. There can be no assurance that the Company will be able to do so or, that NASDAQ will list our shares of common stock for trading even if we do meet the minimum listing requirements.

“Up-listing on the NASDAQ Exchange is a strategic priority for Organicell. We want to ensure liquidity for our shareholders, access to the capital markets to fund our clinical trials and a heightened visibility for our company,” said Albert Mitrani, CEO of Organicell.

ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

FORWARD-LOOKING STATEMENTS

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005424/en/

FAQ

What is Organicell Regenerative Medicine's plan for NASDAQ listing?

Organicell Regenerative Medicine aims to up-list its common stock to the NASDAQ Capital Market to improve liquidity and visibility.

What are the requirements for BPSR to list on NASDAQ?

To list on NASDAQ, Organicell must have at least $5 million in shareholder equity and a minimum trading price of $4.00 per share.

Has Organicell confirmed its NASDAQ listing?

No, there is no guarantee that Organicell will meet NASDAQ's requirements or secure a listing, even if they achieve the financial metrics.

What challenges does Organicell face for up-listing to NASDAQ?

Challenges include the need for capital raising and potential reverse stock splits to meet the trading price criteria.

When was the press release about BPSR's NASDAQ plans issued?

The press release was issued on May 4, 2021.